



A Suresh G Kare Enterprise

INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (E), Mumbai 400 098.

Tel: +91-22-26541851/55 Fax: +91-22-26520787 Email: compliance.officer@indoco.comWebsite: www.indoco.com CIN: L85190MH1947PLC005913

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019

(₹ In Lakhs)

Sr No.	Particulars	Quarter ended 30.06.2019 (Unaudited)	Quarter ended 31.03.2019 (Audited)	Quarter ended 30.06.2018 (Unaudited)	Year ended 31.03.2019 (Audited)
1	Income from Operations				
	(a) Revenue from Operations	24,718	24,500	21,276	94,208
	(b) Other Operating Income	550	705	504	2,637
	Total Income from Operations (Net) (a+b)	25,268	25,205	21,780	96,845
2	Other Income	64	495	30	614
3	Total Income (1+2)	25,331	25,700	21,811	97,459
4	Expenses				
	(a) Cost of materials consumed	6,265	6,798	4,838	24,017
	(b) Purchases of stock-in-trade	1,879	1,094	1,710	6,676
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	417	220	581	1,332
	(d) Employee Benefits expense	6,091	5,807	5,634	23,166
	(e) Research & Development Expense	1,112	1,312	1,321	5,151
	(f) Other Expenses	7,262	7,134	6,555	28,837
	(g) Finance Costs	612	463	718	2,054
	(h) Depreciation and Amortisation expense	1,699	1,947	1,673	7,157
	Total Expenses	25,337	24,774	23,030	98,390
5	Profit/(Loss) before Tax (3-4)	(6)	925	(1,219)	(931)
6	Tax Expenses				
	- Current	4	-	-	-
	- Deferred	(194)	(224)	-	(720)
	- MAT Credit Adjustments	-	-	-	79
	Total Tax Expenses	(190)	(224)	-	(641)
7	Profit/(Loss) for the period (5-6)	185	1,149	(1,219)	(290)
8	Other Comprehensive Income				
a	i) Items that will not be reclassified to profit and loss	(15)	(72)	(3)	(81)
	ii) Income tax on relating to this item	5	25	1	28
b	i) Items that may be reclassified to profit or loss				
	Total Other Comprehensive Income	(10)	(47)	(2)	(53)
9	Total Comprehensive income for the year (7+8)	175	1,103	(1,221)	(343)
	Profit attributable to:				
	Equity Shareholders of the Company	185	1,149	(1,219)	(290)
	Non-Controlling Interest				
		185	1,149	(1,219)	(290)
	Other comprehensive income is attributable to:				
	Equity Shareholders of the Company	(10)	(47)	(2)	(53)
	Non-Controlling Interest				
		(10)	(47)	(2)	(53)
	Total comprehensive income is attributable to:				
	Equity Shareholders of the Company	175	1,103	(1,221)	(343)
	Non-Controlling Interest				
		175	1,103	(1,221)	(343)
10	Paid up Equity Share Capital (Face value ₹ 2/- each)	1843	1843	1843	1843
11	Other Equity				64,219
12	Earnings per share (of ₹ 2/- each)				
	(a) Basic- in ₹	0.20	1.25	(1.32)	(0.31)
	(b) Diluted- in ₹	0.20	1.25	(1.32)	(0.31)

Notes :

1 The unaudited consolidated financial results for the quarter ended 30th June, 2019 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 13th Aug, 2019. The Statutory auditors have expressed an unmodified audit opinion on these standalone and consolidated financial results.

2 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

3 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lakhs)

Net Sales and Income from Operations	Quarter ended 30.06.2019 (Unaudited)	Quarter ended 31.03.2019 (Audited)	Quarter ended 30.06.2018 (Unaudited)	Year ended 31.03.2019 (Audited)
India	17,246	15,804	16,386	65,627
Outside India	7,472	8,696	4,890	28,582
Total	24,718	24,500	21,276	94,208

4 The Consolidated Financial Results includes the Results of the following Companies

Name of the Company	% of Shareholding	Consolidated as
Xtrend Industrial Designers & Engineers Pvt. Ltd.	100	Subsidiary
Indoco Remedies Czech S R O	100	Subsidiary

5 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2019.

6 The figures of the quarter ended 31 March 2019 are balancing figures between audited figures in respect of full financial year 31 March 2019 and the unaudited published year to date figures upto 31 December 2018 which were subjected to limited review.

7 The quarterly consolidated financial results are being submitted for the first time pursuant to the mandatory requirement with effect from April 1, 2019. The consolidated figures for the comparative periods for the quarter ended 30th June, 2018 and the quarter ended 31st March, 2019, as reported in these financial results, have not been subjected to limited review.

8 The Company has adopted IND AS 116, "Leases", effective 1 April 2019, using modified retrospective approach and there is no significant impact on the financial results.

9 There are no exceptional items.

By Order of the Board
For Indoco Remedies Ltd.

sd/-

Suresh G. Kare
ChairmanPlace : Mumbai
Date : 13th Aug, 2019